论文部分内容阅读
目的：了解ＨＢｓＡｇ或Ａｎｔｉ－ＨＣＶ阳性对肾移植受者术后并发肝外感染、急性排异及移植肾功能不全的影响。方法：回顾分析１０１例肾移植受者的临床资料。结果：在ＨＢｓＡｇ（＋）与Ａｎｔｉ－ＨＣＶ（＋）组间上述三大并发症发生率差异不显著（Ｐ＞０．０５）；ＨＢｓＡｇ（＋）组或Ａｎｔｉ－ＨＣＶ（＋）组移植肾急性排异及肾功能不全的发生率较高，尽管较阴性组无显著差异（Ｐ＞０．０５），但肝外感染的发生率明显升高（Ｐ＜０．０５）。结论：对ＨＢｓＡｇ（＋）或Ａｎｔｉ－ＨＣＶ（＋）的肾移植受者必须密切监测肝功能，环孢素Ａ（ＣｓＡ）浓度及机体免疫状态，以选择适当的免疫抑制剂方案及剂量
OBJECTIVE: To investigate the effect of positive HBsAg or Anti-HCV on postoperative liver infection, acute rejection and renal allograft in renal transplant recipients. Methods: The clinical data of 101 renal transplant recipients were retrospectively analyzed. Results: There was no significant difference in the incidence of the three major complications between HBsAg (+) and Anti-HCV (+) groups (P> 0.05) The incidence of rejection and renal insufficiency was higher. Although there was no significant difference between the two groups (P> 0.05), the incidence of extrahepatic infection was significantly higher (P <0.05). CONCLUSIONS: Kidney transplant recipients with HBsAg (+) or Anti-HCV (+) must be closely monitored for liver function, CsA concentration, and immune status in order to select the appropriate immunosuppressive regimen and dose